316 related articles for article (PubMed ID: 16061709)
1. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.
van der Eerden MM; Vlaspolder F; de Graaff CS; Groot T; Bronsveld W; Jansen HM; Boersma WG
Thorax; 2005 Aug; 60(8):672-8. PubMed ID: 16061709
[TBL] [Abstract][Full Text] [Related]
2. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia.
Lee RW; Lindstrom ST
Respirology; 2007 Jan; 12(1):111-6. PubMed ID: 17207035
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
Falguera M; Ruiz-González A; Schoenenberger JA; Touzón C; Gázquez I; Galindo C; Porcel JM
Thorax; 2010 Feb; 65(2):101-6. PubMed ID: 19703825
[TBL] [Abstract][Full Text] [Related]
4. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial.
Schouten JA; Hulscher ME; Trap-Liefers J; Akkermans RP; Kullberg BJ; Grol RP; van der Meer JW
Clin Infect Dis; 2007 Apr; 44(7):931-41. PubMed ID: 17342644
[TBL] [Abstract][Full Text] [Related]
5. [Medical outcomes and antimicrobial compliance according to the Chilean Society of Respiratory Diseases guidelines for hospitalized patients with community acquired pneumonia].
Díaz A; Kuzmanic G; Platzer L; Sanfuentes F; Espinoza MA; Saldías F
Rev Med Chil; 2003 Aug; 131(8):847-56. PubMed ID: 14558238
[TBL] [Abstract][Full Text] [Related]
6. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
[TBL] [Abstract][Full Text] [Related]
7. Addition of macrolide in treating adult hospitalized community-acquired pneumonia.
Loh LC; Quah SY; Khoo SK; Vijayasingham P; Thayaparan T
Respirology; 2005 Jun; 10(3):371-7. PubMed ID: 15955152
[TBL] [Abstract][Full Text] [Related]
8. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia.
Chalmers JD; Singanayagam A; Akram AR; Choudhury G; Mandal P; Hill AT
J Antimicrob Chemother; 2011 Feb; 66(2):416-23. PubMed ID: 21081545
[TBL] [Abstract][Full Text] [Related]
10. Does sputum culture affect the management and/or outcome of community-acquired pneumonia?
Shariatzadeh MR; Marrie TJ
East Mediterr Health J; 2009; 15(4):792-9. PubMed ID: 20187530
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Mokabberi R; Haftbaradaran A; Ravakhah K
J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
[TBL] [Abstract][Full Text] [Related]
12. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
[TBL] [Abstract][Full Text] [Related]
13. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Bratzler DW; Ma A; Nsa W
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
[TBL] [Abstract][Full Text] [Related]
14. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study.
Capelastegui A; España PP; Quintana JM; Gorordo I; Ortega M; Idoiaga I; Bilbao A
Clin Infect Dis; 2004 Oct; 39(7):955-63. PubMed ID: 15472846
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
16. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
17. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
18. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
[TBL] [Abstract][Full Text] [Related]
19. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors.
Schouten JA; Hulscher ME; Kullberg BJ; Cox A; Gyssens IC; van der Meer JW; Grol RP
J Antimicrob Chemother; 2005 Sep; 56(3):575-82. PubMed ID: 16049096
[TBL] [Abstract][Full Text] [Related]
20. [Treatment and course of community-acquired pneumonia caused by atypical pathogens].
Fernández Alvarez R; Suárez Toste I; Rubinos Cuadrado G; Medina Gonzálvez A; Gullón Blanco JA; González Martín I
Arch Bronconeumol; 2006 Sep; 42(9):430-3. PubMed ID: 17040657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
